申请人:Charrier Jean-Damien
公开号:US20090023739A1
公开(公告)日:2009-01-22
This invention provides novel caspase inhibitors of formula I:
wherein R
1
is hydrogen, CHN
2
, R, or —CH
2
Y; R is an aliphatic group, an aryl group, an aralkyl group, a heterocyclyl group, or a heterocyclylalkyl group; Y is an electronegative leaving group; R
2
is CO
2
H, CH
2
CO
2
H, or esters, amides or isosteres thereof; X
2
—X
1
is N(R
3
)—C(R
3
), C(R
3
)
2
—C(R
3
), C(R
3
)
2
—N, N═C, C(R
3
)═C, C(═O)—N, or C(═O)—C(R
3
); each R
3
is independently selected from hydrogen or C
1-6
aliphatic; Ring C is a fused aryl ring; n is 0, 1 or 2; and each methylene carbon in Ring A is optionally and independently substituted by ═O, or one or more halogen, C
1-4
alkyl, or C
1-4
alkoxy. The compounds are useful for treating caspase-mediated diseases.
本发明提供了一种新颖的caspase抑制剂,其化学式为I:其中R1为氢、CHN2、R或—CH2Y;R为脂肪基、芳基、芳基烷基、杂环基或杂环基烷基;Y为电负性离去基团;R2为CO2H、CH2CO2H或其酯、酰胺或同分异构体;X2—X1为N(R3)—C(R3)、C(R3)2—C(R3)、C(R3)2—N、N═C、C(R3)═C、C(═O)—N或C(═O)—C(R3);每个R3独立地选择自氢或C1-6脂肪基;环C为融合的芳基环;n为0、1或2;环A中的每个亚甲基碳原子可选且独立地被═O、一个或多个卤素、C1-4烷基或C1-4烷氧基取代。这些化合物可用于治疗caspase介导的疾病。